Welcome to our dedicated page for Precigen SEC filings (Ticker: PGEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Precigen, Inc. filings document the company’s biopharmaceutical operations, commercial product disclosures, governance matters, and capital structure. Form 8-K reports cover financial results, PAPZIMEOS business updates, investor presentations, commercial supply arrangements, and financing agreements tied to the company’s transition into commercial-stage operations.
Precigen’s proxy materials describe board elections, auditor ratification, executive compensation votes, and equity incentive plan matters. Other filings disclose its Nasdaq-listed common stock, preferred-stock conversion activity, senior secured debt arrangements, material agreements, risk factors, and corporate governance controls relevant to a public precision-medicine company.
Randal J. Kirk, a director and 10% owner of Precigen, Inc. (PGEN), reported multiple transactions in mid-September 2025. On 09/17/2025 the reporting person received 25,000 shares of 8.00% Series A Convertible Perpetual Preferred Stock sold in a private placement, convertible into 17,385,257 common shares at a conversion mechanism described in the agreement. On 09/18/2025 and 09/19/2025 the reporting person (through entities he controls) sold a total of 5,000,252 common shares: 1,403,360 shares at a weighted average price of $3.86 and 3,596,892 shares at a weighted average price of $3.68. The filing lists multiple entities controlled by Mr. Kirk that hold beneficial ownership interests and disclaims direct beneficial ownership except for pecuniary interest.
Randal J. Kirk, a director and 10% owner of Precigen, Inc. (PGEN), reported multiple transactions in mid-September 2025. On 09/17/2025 the reporting person received 25,000 shares of 8.00% Series A Convertible Perpetual Preferred Stock sold in a private placement, convertible into 17,385,257 common shares at a conversion mechanism described in the agreement. On 09/18/2025 and 09/19/2025 the reporting person (through entities he controls) sold a total of 5,000,252 common shares: 1,403,360 shares at a weighted average price of $3.86 and 3,596,892 shares at a weighted average price of $3.68. The filing lists multiple entities controlled by Mr. Kirk that hold beneficial ownership interests and disclaims direct beneficial ownership except for pecuniary interest.
Precigen, Inc. (PGEN) Form 144 notifies the market of a proposed sale of 252 common shares on Nasdaq with an aggregate market value of $970, against 297,972,920 shares outstanding. The filer reports acquiring 3,112,507 shares on 07/03/2018 in a public offering for cash.
The filing also discloses that Kapital Joe, LLC (Randal J. Kirk as agent) sold 1,403,360 common shares on 09/18/2025 for gross proceeds of $5,422,348. The signer certifies no undisclosed material adverse information and attests to the accuracy of the notice.
Precigen, Inc. (PGEN) Form 144 notifies the market of a proposed sale of 252 common shares on Nasdaq with an aggregate market value of $970, against 297,972,920 shares outstanding. The filer reports acquiring 3,112,507 shares on 07/03/2018 in a public offering for cash.
The filing also discloses that Kapital Joe, LLC (Randal J. Kirk as agent) sold 1,403,360 common shares on 09/18/2025 for gross proceeds of $5,422,348. The signer certifies no undisclosed material adverse information and attests to the accuracy of the notice.
Precigen, Inc. (PGEN) filed a Form 144 notice reporting a proposed sale of 5,000,000 common shares with an aggregate market value of $19,625,000. The filing lists the broker as Charles Schwab Corp and names Nasdaq as the exchange, with an approximate sale date of 09/18/2025. The filing discloses the acquisition history for the shares being sold, showing multiple purchases and initial/public offerings between 2013 and 2018 that total the lots listed. The filer reports 297,972,920 shares outstanding, and notes there were no securities sold in the past three months. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.
Precigen, Inc. (PGEN) filed a Form 144 notice reporting a proposed sale of 5,000,000 common shares with an aggregate market value of $19,625,000. The filing lists the broker as Charles Schwab Corp and names Nasdaq as the exchange, with an approximate sale date of 09/18/2025. The filing discloses the acquisition history for the shares being sold, showing multiple purchases and initial/public offerings between 2013 and 2018 that total the lots listed. The filer reports 297,972,920 shares outstanding, and notes there were no securities sold in the past three months. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.
Precigen, Inc. reported that on September 15, 2025, holders of its 8.00% Series A Convertible Perpetual Preferred Stock converted 79,000 preferred shares, with an aggregate stated value of $79,000,000, into 54,937,411 shares of common stock. The common shares were delivered on September 17, 2025 under the existing conversion terms, using a rate of 695.4103 common shares per $1,000 of stated value.
The exchange was conducted with existing security holders and relied on the exemption from registration in Section 3(a)(9) of the Securities Act of 1933, with no commission or other remuneration paid for soliciting the exchange.
Precigen, Inc. reported that on September 15, 2025, holders of its 8.00% Series A Convertible Perpetual Preferred Stock converted 79,000 preferred shares, with an aggregate stated value of $79,000,000, into 54,937,411 shares of common stock. The common shares were delivered on September 17, 2025 under the existing conversion terms, using a rate of 695.4103 common shares per $1,000 of stated value.
The exchange was conducted with existing security holders and relied on the exemption from registration in Section 3(a)(9) of the Securities Act of 1933, with no commission or other remuneration paid for soliciting the exchange.
Helen Sabzevari, President and CEO and a director of Precigen, Inc. (PGEN), reported the vesting of performance stock units. On 09/12/2025, the second installment of PSUs granted August 28, 2024 vested, resulting in 825,000 shares of common stock being issued or payable in cash equivalent value. The filing lists the shares as directly owned following the transaction. The Form 4 was signed on behalf of Ms. Sabzevari by an attorney-in-fact and filed on 09/16/2025. The document states each PSU converts to one share or an equivalent cash amount.
Harry Thomasian Jr., Chief Financial Officer of Precigen, Inc. (PGEN), reported the vesting of 125,000 performance stock units (PSUs) on 09/12/2025. These PSUs were part of a grant made on August 28, 2024; the filing states the second installment vested after meeting the applicable performance condition. Each PSU may be settled in one share of the company’s common stock or an equivalent cash amount. Following the reported transaction, Mr. Thomasian directly beneficially owns 125,000 shares attributable to these vested PSUs. The Form 4 was signed on 09/16/2025.
Donald P. Lehr, Chief Legal Officer of Precigen, Inc. (PGEN), reported the vesting of 54,000 performance stock units (PSUs) on 09/12/2025. The filing shows those PSUs converted into 54,000 shares of the issuer's common stock (or an equivalent cash amount) at a reported price of $0, resulting in direct beneficial ownership of 54,000 shares following the transaction. The PSUs represent the second installment of an award originally granted on August 28, 2024 and vested based on achievement of the applicable performance condition for that installment. The form is signed by Mr. Lehr on 09/16/2025.
Phil Tennant, Precigen Chief Commercial Officer, reported the vesting of 25,000 performance stock units (PSUs) on 09/12/2025 that converted to common stock. The Form 4 shows these PSUs were part of an award originally granted August 28, 2024 and represent the second installment that vested after achievement of the applicable performance condition. Each PSU is payable in one share of the issuer's common stock or a cash equivalent. Following the reported transaction, Mr. Tennant beneficially owns 25,000 shares of Precigen common stock. The Form 4 was signed by attorney-in-fact Donald P. Lehr on 09/16/2025.
Rutul R. Shah, Chief Operating Officer of Precigen, Inc. (PGEN), reported the vesting of 125,000 performance stock units on 09/12/2025. The filing shows these units are the second installment of PSUs originally granted on August 28, 2024 and vested upon achievement of the applicable performance condition for that installment. Each PSU is payable in one share of common stock or a cash equivalent. Following the reported transaction the filing lists 125,000 shares beneficially owned as a direct holding. The Form 4 is signed on behalf of Mr. Shah by an attorney-in-fact on 09/16/2025.
Nancy H. Agee, a director of Precigen, Inc. (PGEN), reported purchasing 15,000 shares of the company's common stock on 09/04/2025 at a price of $4.60 per share. After the purchase she beneficially owns 217,841 shares, held directly. The filing shows no derivative transactions and was signed on 09/05/2025 by Nancy H. Agee via attorney-in-fact.